Effectiveness of renoprotective approaches for persistent proteinuria in lupus nephritis: more than just immunosuppression

Objective The objective of this study is to evaluate the efficacy of a tightly controlled renoprotective protocol in systemic lupus erythematosus (SLE) patients with persistent proteinuria. Methods Thirteen SLE patients with nephritis and persistent proteinuria (>1 g/24 hours) were included. The...

Full description

Saved in:
Bibliographic Details
Published in:Lupus 2018-12, Vol.27 (14), p.2215-2219
Main Authors: Castro, M, Ugolini-Lopes, M, Borba, E F, Bonfá, E, Seguro, L P C
Format: Article
Language:English
Subjects:
Adult
Angiotensin-converting enzyme inhibitors
Antihypertensives
Azathioprine
Azathioprine - therapeutic use
Blood pressure
Blood Pressure - drug effects
Brazil
Creatinine
Drug Therapy, Combination
Female
Glucocorticoids
Humans
Immunosuppression
Immunosuppressive agents
Immunosuppressive Agents - therapeutic use
Lupus
Lupus nephritis
Lupus Nephritis - complications
Lupus Nephritis - drug therapy
Male
Middle Aged
Mycophenolate mofetil
Mycophenolic acid
Mycophenolic Acid - therapeutic use
Nephritis
Patients
Peptidyl-dipeptidase A
Prednisone
Prednisone - administration & dosage
Proteinuria
Proteinuria - drug therapy
Severity of Illness Index
Smoking
Systemic lupus erythematosus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective The objective of this study is to evaluate the efficacy of a tightly controlled renoprotective protocol in systemic lupus erythematosus (SLE) patients with persistent proteinuria. Methods Thirteen SLE patients with nephritis and persistent proteinuria (>1 g/24 hours) were included. The protocol consisted of regular clinical evaluations every two weeks to assess blood pressure (BP, target 130/80mmHg at baseline. At the end, 11 patients (84.6%) achieved stable BP target; 92.3% were using an angiotensin-converting enzyme inhibitor, 53.9% an angiotensin receptor blocker, and 46.2% were using combined therapy. All patients had a significant reduction in proteinuria levels (2.26 ± 1.09 vs 0.88 ± 0.54 g/24 hours, p 
ISSN:0961-2033
1477-0962
DOI:10.1177/0961203318809883